Rheumatoid Arthritis
Conditions
Keywords
Rheumatoid arthritis, etanercept, methotrexate, infliximab, adalimumab, anti-drug antibody
Brief summary
The first 12 weeks of this study will compare the efficacy of etanercept 50 mg once-weekly to placebo in subjects with rheumatoid arthritis who have not responded well to infliximab or adalimumab plus methotrexate. This comparison will be performed for all subjects and separately for subjects who are anti-drug antibody positive for one of these medications. From week 12 to week 24, all subjects will receive etanercept 50 mg once-weekly. The effect of anti-drug antibody status on the efficacy of etanercept as well as the safety profile of etanercept in these subjects will also be evaluated throughout the study.
Detailed description
This study was prematurely terminated on June 25, 2014 due to significant and continuing delays in achieving the study B1801355 enrolment target. The decision to stop the study was not driven by any safety concerns.
Interventions
DRUGEtanercept
Etanercept 50 mg once-weekly
DRUGPlacebo
Etanercept placebo once-weekly
Sponsors
Pfizer
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 79 Years
Healthy volunteers
No
Inclusion criteria
1. Met the 1987 ACR Revised Criteria for RA 2. A history of inadequate response to infliximab or adalimumab in combination with methotrexate. 3. A stable dose of oral methotrexate for at least 6 weeks before the baseline visit.
Exclusion criteria
1. ACR functional class IV 2. Prior treatment with etanercept; both infliximab and adalimumab; or any immunosuppressive biologic agent other than infliximab or adalimumab. 3. Discontinuation of infliximab or adalimumab for a primary reason other than inadequate efficacy response.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in the Disease Activity Score Based on a 28 Joint Count (DAS28-C-reactive Protein [CRP]) at Week 12. | Baseline, 12 weeks | DAS28 calculated from the number of swollen joints (SJC) and painful joints (PJC) using the 28 joints count, the c-reactive protein (CRP) and Subject General Health Visual Analogue Scale (VAS) assessment (participant rated health assessment with scores ranging 0 to 100; higher scores indicate worse health status). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With DAS28 <3.2 | 12 weeks, 24 weeks | Number of participants with DAS28 \<3.2. A score of \< 3.2 implied low disease activity. |
| Number of Participants With DAS28 <2.6 | 12 weeks, 24 weeks | Number of Participants with DAS28 \<2.6. A DAS28 \< 2.6 implies remission. |
| Number of Participants Achieving American College of Rheumatology 20% (ACR20) Response | 12 weeks, 24 weeks | ACR20 response: greater than or equal to (≥) 20 percent (%) improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of 5 remaining ACR core measures: participant's assessment of pain; Subject Global Assessment (SGA) of disease activity; Physician Global Assessment (PGA) of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and CRP. |
| Number of Participants Achieving American College of Rheumatology 50% (ACR50) Response | 12 weeks, 24 weeks | ACR50 response: greater than or equal to (≥) 50 percent (%) improvement in tender or swollen joint counts and ≥ 50% improvement in 3 of the 5 remaining ACR core measures: participant's assessment of pain; SGA of disease activity; PGA of disease activity; subject's assessment of functional disability via a HAQ; and CRP. |
| Number of Participants Achieving American College of Rheumatology 70% (ACR70) Response | 12 weeks, 24 weeks | ACR70 response: greater than or equal to (≥) 70 percent (%) improvement in tender or swollen joint counts and ≥ 70% improvement in 3 of the 5 remaining ACR core measures: participant's assessment of pain; SGA of disease activity; PGA of disease activity; subject's assessment of functional disability via a HAQ; and CRP. |
| Number of Participants Achieving American College of Rheumatology 90% (ACR90) Response | 12 weeks, 24 weeks | ACR90 response: greater than or equal to (≥) 90 percent (%) improvement in tender or swollen joint counts and ≥ 90% improvement in 3 of the 5 remaining ACR core measures: participant's assessment of pain; SGA of disease activity; PGA of disease activity; subject's assessment of functional disability via a HAQ; and CRP. |
| Number of Participants Achieving European League Against Rheumatism (EULAR) Good and/or Moderate Response. | 12 weeks, 24 weeks | The Disease Activity Score Based on 28-joints Count based (DAS28-based) EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline \>1.2 with DAS28 =\< 3.2; moderate responders: change from baseline \>1.2 with DAS28 \>3.2 to =\<5.1 or change from baseline \>0.6 to =\<1.2 with DAS28 =\<5.1; non-responders: change from baseline =\< 0.6 or change from baseline \>0.6 and =\<1.2 with DAS28 \>5.1. |
| Number of Participants Achieving Low Disease Activity or Remission Based on Clinical Disease Activity Index (CDAI) | 12 weeks, 24 weeks | The CDAI is the numerical sum of 4 outcome parameters: tender joint count (TJC) and SJC based on a 28-joint assessment, SGA and PGA assessed on 0-10 point scale; higher scores=greater affliction due to disease activity. CDAI total score = 0-76. CDAI \<= 2.8 indicates disease remission, \>2.8 to 10 = low disease activity, \>10 to 22 = moderate disease activity, and \>22 = high disease activity. |
| Number of Participants Achieving Low Disease Activity or Remission Based on Simplified Disease Activity Index (SDAI). | 12 weeks, 24 weeks | The SDAI is the numerical sum of five outcome parameters: TJC) and SJC based on a 28-joint assessment, SGA and PGA assessed on 0-10 point scale; higher scores=greater affliction due to disease activity, and CRP (mg/dL). SDAI total score= 0-86. SDAI \<=3.3 indicates disease remission, \>3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high disease activity. |
| Change From Baseline in CDAI | Baseline, 12 weeks, 24 weeks | Change from Baseline in CDAI scores was to be calculated. The CDAI is the numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, SGA and PGA assessed on 0-10 point scale; higher scores=greater affliction due to disease activity. CDAI total score = 0-76. CDAI \<= 2.8 indicates disease remission, \>2.8 to 10 = low disease activity, \>10 to 22 = moderate disease activity, and \>22 = high disease activity. |
| Change From Baseline in SDAI. | Baseline, 12 weeks, 24 weeks | Change from Baseline in SDAI scores were to be calculated. The SDAI is the numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, SGA and PGA assessed on 0-10 point scale; higher scores=greater affliction due to disease activity, and CRP (mg/dL). SDAI total score= 0-86. SDAI \<=3.3 indicates disease remission, \>3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high disease activity. |
| Change From Baseline in Number of Tender/Painful Joints | Baseline, 12 weeks, 24 weeks | Change from Baseline in the number of tender/painful joints using the 28 joint count including shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints, and knees was to be calculated. |
| Change From Baseline in the DAS28 at Week 24 | Baseline, 24 weeks | DAS28 calculated from the number of SJC and PJC using the 28 joints count, the CRP and and Subject General Health VAS assessment (participant rated health assessment with scores ranging 0 to 100; higher scores indicate worse health status). |
| Change From Baseline in Physician Global Assessment of Disease Activity | Baseline, 12 weeks, 24 weeks | Change from Baseline in the PGA scores was to be estimated. The Study Physician estimated the participant's overall disease activity over the last 2 to 3 days using a scale between 0 (no disease activity) and 10 (extreme disease activity). |
| Change From Baseline in Subject Global Assessment of Disease Activity | Baseline, 12 weeks, 24 weeks | Change from Baseline in Subject Global Assessment of Disease Activity was to be estimated. Participants were to assess their overall disease activity over the last 2 to 3 days using a scale between 0 (no disease activity) and 10 (extreme disease activity). |
| Change From Baseline in Subject General Health VAS. | Baseline, 12 weeks, 24 weeks | Subject General Health VAS assessment (participant rated health assessment with scores ranging 0 to 100; higher scores indicate worse health status). |
| Change From Baseline in Subject Pain | Baseline, 12 weeks, 24 weeks | Subject Pain was to be measured on a 0 to 100 mm Visual Analog Scale (VAS), with 0 mm = no pain and 100 mm = most severe pain. |
| Change From Baseline in CRP | Baseline, 12 weeks, 24 weeks | The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement. |
| Change From Baseline in Health Assessment Questionnaire Disability and Discomfort Scales (HAQ-DI) | Baseline, 12 weeks, 24 weeks | Health Assessment Questionnaire-Disability Index (HAQ-DI): participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty. |
| Change From Baseline in Euro Quality of Life (Qol) EQ-5 Dimensions Questionnaire (EQ-5D) | Baseline, 12 weeks, 24 weeks | The EuroQol-5 Dimensions (EQ-5D) is a participant-completed questionnaire designed to assess health related quality of life. There are 2 components to the EQ-5D: a Health State Profile and a VAS. For the Health State Profile, participants recorded their level of current health for 5 domains comprising a health profile: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Scores from the 5 domains may be used to calculate a single index value, also known as a utility score. On the VAS participants were asked to rate their current health on a scale from 0 to 100 mm, where 0 represented the worst imaginable health state and 100 represented the best imaginable health state. In addition to a summary of mean changes, 1 categorical endpoint each based on EQ-5D utility score and 1 based on the VAS were derived and analyzed: EQ-5D utility score improvement ≥0.05 and EQ-5D VAS score \>82. |
| Change From Baseline in Short Form-36 Health Survey (SF-36) | Baseline, 12 weeks, 24 weeks | The 36-Item Short Form Health Survey (SF-36) is widely used 36-item questionnaire that measures general health-related quality of life in the following 8 domains: physical function, role limitations due to physical health, bodily pain, general health perception, vitality, social functioning, role limitation due to emotional problems, and mental health. Scores for the 8 domains range from 0 to 100 where higher scores are better. |
| Change From Baseline in Patient Acceptable Symptom State (PASS) | Baseline, 12 weeks, 24 weeks | The Patient Acceptable Symptom State (PASS) was a participant-completed form in which participants were asked to Think about all the ways your rheumatoid arthritis (RA) has affected you during the last 48 hours. If you were to remain in the next few months as you were during the last 48 hours, would this be acceptable or unacceptable to you? The participant indicated a response of either acceptable or unacceptable. |
| Change From Baseline in Vectra Disease Activity Levels | Baseline, 12 weeks, 24 weeks | The change from Baseline in Vectra disease activity levels was to be estimated. The assessment measures serum protein biomarkers associated with RA. It has a range from 1-100 with lower scores indicating the better outcome. |
| Number of Participants With Positive Etanercept Anti-drug Antibody Status | Baseline, 12 weeks, 24 weeks | Blood samples (6 mL) were collected at the baseline, Week 12, and Week 24 visits, or upon early withdrawal, to provide a minimum of 1 mL serum each for ETN ADA and ETN neutralizing antibody analyses. Samples which were positive for ETN anti-drug antibodies were then also tested for ETN neutralizing antibodies. |
| Number of Participants With Positive Etanercept Neutralizing Anti-drug Antibody Status | Baseline, 12 weeks, 24 weeks | Blood samples (6 mL) were collected at the baseline, Week 12, and Week 24 visits, or upon early withdrawal, to provide a minimum of 1 mL serum each for ETN ADA and ETN neutralizing antibody analyses. Samples which were positive for ETN anti-drug antibodies were then also tested for ETN neutralizing antibodies. |
| Change From Baseline in Number of Swollen Joints | Baseline, 12 weeks, 24 weeks | Change from Baseline in the number of swollen joints including shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints, and knees was to be calculated. |
Countries
Australia, Belgium, France, Hong Kong, Israel, Russia, Spain
Participant flow
Recruitment details
In this 24 week, multicenter, randomized, double-blind, placebo-controlled (Period 1), 2 period study, a total of 20 participants were screened, out of which 16 participants were randomized. Due to delayed enrollment and an insufficient number of participants, recruitment was terminated.
Pre-assignment details
Eleven participants were randomly assigned to etanercept \[ETN\] and 5 participants to placebo in the blinded treatment period. A total of 11 participants (9 ETN treated and 2 placebo treated) completed the blinded treatment period and entered the open label treatment with ETN. One of the 2 placebo treated participants entered the Escape Arm.
Participants by arm
| Arm | Count |
|---|---|
| Period I - Blinded Treatment - Etanercept Participants received etanercept 50 mg subcutaneously with oral methotrexate tablets once-weekly. | 11 |
| Period I - Blinded Treatment - Placebo Participants received placebo injections with oral methotrexate tablets once-weekly. | 5 |
| Total | 16 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Blinded Treatment | Adverse Event | 0 | 1 | 0 |
| Blinded Treatment | Protocol Violation | 0 | 1 | 0 |
| Blinded Treatment | Study Terminated by Sponsor | 2 | 0 | 0 |
| Blinded Treatment | Withdrawal by Subject | 0 | 1 | 0 |
| Open Label Treatment | Study Terminated by Sponsor | 0 | 0 | 6 |
Baseline characteristics
| Characteristic | Period I - Blinded Treatment - Etanercept | Period I - Blinded Treatment - Placebo | Total |
|---|---|---|---|
| Age, Continuous | 54.5 Years STANDARD_DEVIATION 13.43 | 54.8 Years STANDARD_DEVIATION 19.56 | 54.6 Years STANDARD_DEVIATION 14.91 |
| Sex: Female, Male Female | 8 Participants | 4 Participants | 12 Participants |
| Sex: Female, Male Male | 3 Participants | 1 Participants | 4 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 5 / 11 | 3 / 5 | 4 / 11 |
| serious Total, serious adverse events | 0 / 11 | 0 / 5 | 0 / 11 |
Outcome results
Primary
Change From Baseline in the Disease Activity Score Based on a 28 Joint Count (DAS28-C-reactive Protein [CRP]) at Week 12.
DAS28 calculated from the number of swollen joints (SJC) and painful joints (PJC) using the 28 joints count, the c-reactive protein (CRP) and Subject General Health Visual Analogue Scale (VAS) assessment (participant rated health assessment with scores ranging 0 to 100; higher scores indicate worse health status).
Time frame: Baseline, 12 weeks
Population: Due to small sample size, Pfizer did not perform statistical analysis.
Secondary
Change From Baseline in CDAI
Change from Baseline in CDAI scores was to be calculated. The CDAI is the numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, SGA and PGA assessed on 0-10 point scale; higher scores=greater affliction due to disease activity. CDAI total score = 0-76. CDAI \<= 2.8 indicates disease remission, \>2.8 to 10 = low disease activity, \>10 to 22 = moderate disease activity, and \>22 = high disease activity.
Time frame: Baseline, 12 weeks, 24 weeks
Population: Due to small sample size, Pfizer did not perform statistical analysis.
Secondary
Change From Baseline in CRP
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.
Time frame: Baseline, 12 weeks, 24 weeks
Population: Due to small sample size, Pfizer did not perform statistical analysis.
Secondary
Change From Baseline in Euro Quality of Life (Qol) EQ-5 Dimensions Questionnaire (EQ-5D)
The EuroQol-5 Dimensions (EQ-5D) is a participant-completed questionnaire designed to assess health related quality of life. There are 2 components to the EQ-5D: a Health State Profile and a VAS. For the Health State Profile, participants recorded their level of current health for 5 domains comprising a health profile: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Scores from the 5 domains may be used to calculate a single index value, also known as a utility score. On the VAS participants were asked to rate their current health on a scale from 0 to 100 mm, where 0 represented the worst imaginable health state and 100 represented the best imaginable health state. In addition to a summary of mean changes, 1 categorical endpoint each based on EQ-5D utility score and 1 based on the VAS were derived and analyzed: EQ-5D utility score improvement ≥0.05 and EQ-5D VAS score \>82.
Time frame: Baseline, 12 weeks, 24 weeks
Population: Due to small sample size, Pfizer did not perform statistical analysis.
Secondary
Change From Baseline in Health Assessment Questionnaire Disability and Discomfort Scales (HAQ-DI)
Health Assessment Questionnaire-Disability Index (HAQ-DI): participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
Time frame: Baseline, 12 weeks, 24 weeks
Population: Due to small sample size, Pfizer did not perform statistical analysis.
Secondary
Change From Baseline in Number of Swollen Joints
Change from Baseline in the number of swollen joints including shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints, and knees was to be calculated.
Time frame: Baseline, 12 weeks, 24 weeks
Population: Due to small sample size, Pfizer did not perform statistical analysis.
Secondary
Change From Baseline in Number of Tender/Painful Joints
Change from Baseline in the number of tender/painful joints using the 28 joint count including shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints, and knees was to be calculated.
Time frame: Baseline, 12 weeks, 24 weeks
Population: Due to small sample size, Pfizer did not perform statistical analysis.
Secondary
Change From Baseline in Patient Acceptable Symptom State (PASS)
The Patient Acceptable Symptom State (PASS) was a participant-completed form in which participants were asked to Think about all the ways your rheumatoid arthritis (RA) has affected you during the last 48 hours. If you were to remain in the next few months as you were during the last 48 hours, would this be acceptable or unacceptable to you? The participant indicated a response of either acceptable or unacceptable.
Time frame: Baseline, 12 weeks, 24 weeks
Population: Due to small sample size, Pfizer did not perform statistical analysis.
Secondary
Change From Baseline in Physician Global Assessment of Disease Activity
Change from Baseline in the PGA scores was to be estimated. The Study Physician estimated the participant's overall disease activity over the last 2 to 3 days using a scale between 0 (no disease activity) and 10 (extreme disease activity).
Time frame: Baseline, 12 weeks, 24 weeks
Population: Due to small sample size, Pfizer did not perform statistical analysis.
Secondary
Change From Baseline in SDAI.
Change from Baseline in SDAI scores were to be calculated. The SDAI is the numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, SGA and PGA assessed on 0-10 point scale; higher scores=greater affliction due to disease activity, and CRP (mg/dL). SDAI total score= 0-86. SDAI \<=3.3 indicates disease remission, \>3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high disease activity.
Time frame: Baseline, 12 weeks, 24 weeks
Population: Due to small sample size, Pfizer did not perform statistical analysis.
Secondary
Change From Baseline in Short Form-36 Health Survey (SF-36)
The 36-Item Short Form Health Survey (SF-36) is widely used 36-item questionnaire that measures general health-related quality of life in the following 8 domains: physical function, role limitations due to physical health, bodily pain, general health perception, vitality, social functioning, role limitation due to emotional problems, and mental health. Scores for the 8 domains range from 0 to 100 where higher scores are better.
Time frame: Baseline, 12 weeks, 24 weeks
Population: Due to small sample size, Pfizer did not perform statistical analysis.
Secondary
Change From Baseline in Subject General Health VAS.
Subject General Health VAS assessment (participant rated health assessment with scores ranging 0 to 100; higher scores indicate worse health status).
Time frame: Baseline, 12 weeks, 24 weeks
Population: Due to small sample size, Pfizer did not perform statistical analysis.
Secondary
Change From Baseline in Subject Global Assessment of Disease Activity
Change from Baseline in Subject Global Assessment of Disease Activity was to be estimated. Participants were to assess their overall disease activity over the last 2 to 3 days using a scale between 0 (no disease activity) and 10 (extreme disease activity).
Time frame: Baseline, 12 weeks, 24 weeks
Population: Due to small sample size, Pfizer did not perform statistical analysis.
Secondary
Change From Baseline in Subject Pain
Subject Pain was to be measured on a 0 to 100 mm Visual Analog Scale (VAS), with 0 mm = no pain and 100 mm = most severe pain.
Time frame: Baseline, 12 weeks, 24 weeks
Population: Due to small sample size, Pfizer did not perform statistical analysis.
Secondary
Change From Baseline in the DAS28 at Week 24
DAS28 calculated from the number of SJC and PJC using the 28 joints count, the CRP and and Subject General Health VAS assessment (participant rated health assessment with scores ranging 0 to 100; higher scores indicate worse health status).
Time frame: Baseline, 24 weeks
Population: Due to small sample size, Pfizer did not perform statistical analysis.
Secondary
Change From Baseline in Vectra Disease Activity Levels
The change from Baseline in Vectra disease activity levels was to be estimated. The assessment measures serum protein biomarkers associated with RA. It has a range from 1-100 with lower scores indicating the better outcome.
Time frame: Baseline, 12 weeks, 24 weeks
Population: Vectra disease activity analysis of laboratory samples was not conducted due to study termination.
Secondary
Number of Participants Achieving American College of Rheumatology 20% (ACR20) Response
ACR20 response: greater than or equal to (≥) 20 percent (%) improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of 5 remaining ACR core measures: participant's assessment of pain; Subject Global Assessment (SGA) of disease activity; Physician Global Assessment (PGA) of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and CRP.
Time frame: 12 weeks, 24 weeks
Population: Due to small sample size, Pfizer did not perform statistical analysis.
Secondary
Number of Participants Achieving American College of Rheumatology 50% (ACR50) Response
ACR50 response: greater than or equal to (≥) 50 percent (%) improvement in tender or swollen joint counts and ≥ 50% improvement in 3 of the 5 remaining ACR core measures: participant's assessment of pain; SGA of disease activity; PGA of disease activity; subject's assessment of functional disability via a HAQ; and CRP.
Time frame: 12 weeks, 24 weeks
Population: Due to small sample size, Pfizer did not perform statistical analysis.
Secondary
Number of Participants Achieving American College of Rheumatology 70% (ACR70) Response
ACR70 response: greater than or equal to (≥) 70 percent (%) improvement in tender or swollen joint counts and ≥ 70% improvement in 3 of the 5 remaining ACR core measures: participant's assessment of pain; SGA of disease activity; PGA of disease activity; subject's assessment of functional disability via a HAQ; and CRP.
Time frame: 12 weeks, 24 weeks
Population: Due to small sample size, Pfizer did not perform statistical analysis.
Secondary
Number of Participants Achieving American College of Rheumatology 90% (ACR90) Response
ACR90 response: greater than or equal to (≥) 90 percent (%) improvement in tender or swollen joint counts and ≥ 90% improvement in 3 of the 5 remaining ACR core measures: participant's assessment of pain; SGA of disease activity; PGA of disease activity; subject's assessment of functional disability via a HAQ; and CRP.
Time frame: 12 weeks, 24 weeks
Population: Due to small sample size, Pfizer did not perform statistical analysis.
Secondary
Number of Participants Achieving European League Against Rheumatism (EULAR) Good and/or Moderate Response.
The Disease Activity Score Based on 28-joints Count based (DAS28-based) EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline \>1.2 with DAS28 =\< 3.2; moderate responders: change from baseline \>1.2 with DAS28 \>3.2 to =\<5.1 or change from baseline \>0.6 to =\<1.2 with DAS28 =\<5.1; non-responders: change from baseline =\< 0.6 or change from baseline \>0.6 and =\<1.2 with DAS28 \>5.1.
Time frame: 12 weeks, 24 weeks
Population: Due to small sample size, Pfizer did not perform statistical analysis.
Secondary
Number of Participants Achieving Low Disease Activity or Remission Based on Clinical Disease Activity Index (CDAI)
The CDAI is the numerical sum of 4 outcome parameters: tender joint count (TJC) and SJC based on a 28-joint assessment, SGA and PGA assessed on 0-10 point scale; higher scores=greater affliction due to disease activity. CDAI total score = 0-76. CDAI \<= 2.8 indicates disease remission, \>2.8 to 10 = low disease activity, \>10 to 22 = moderate disease activity, and \>22 = high disease activity.
Time frame: 12 weeks, 24 weeks
Population: Due to small sample size, Pfizer did not perform statistical analysis.
Secondary
Number of Participants Achieving Low Disease Activity or Remission Based on Simplified Disease Activity Index (SDAI).
The SDAI is the numerical sum of five outcome parameters: TJC) and SJC based on a 28-joint assessment, SGA and PGA assessed on 0-10 point scale; higher scores=greater affliction due to disease activity, and CRP (mg/dL). SDAI total score= 0-86. SDAI \<=3.3 indicates disease remission, \>3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high disease activity.
Time frame: 12 weeks, 24 weeks
Population: Due to small sample size, Pfizer did not perform statistical analysis.
Secondary
Number of Participants With DAS28 <2.6
Number of Participants with DAS28 \<2.6. A DAS28 \< 2.6 implies remission.
Time frame: 12 weeks, 24 weeks
Population: Due to small sample size, Pfizer did not perform statistical analysis.
Secondary
Number of Participants With DAS28 <3.2
Number of participants with DAS28 \<3.2. A score of \< 3.2 implied low disease activity.
Time frame: 12 weeks, 24 weeks
Population: Due to small sample size, Pfizer did not perform statistical analysis.
Secondary
Number of Participants With Positive Etanercept Anti-drug Antibody Status
Blood samples (6 mL) were collected at the baseline, Week 12, and Week 24 visits, or upon early withdrawal, to provide a minimum of 1 mL serum each for ETN ADA and ETN neutralizing antibody analyses. Samples which were positive for ETN anti-drug antibodies were then also tested for ETN neutralizing antibodies.
Time frame: Baseline, 12 weeks, 24 weeks
Population: Due to small sample size, Pfizer did not perform statistical analysis.
Secondary
Number of Participants With Positive Etanercept Neutralizing Anti-drug Antibody Status
Blood samples (6 mL) were collected at the baseline, Week 12, and Week 24 visits, or upon early withdrawal, to provide a minimum of 1 mL serum each for ETN ADA and ETN neutralizing antibody analyses. Samples which were positive for ETN anti-drug antibodies were then also tested for ETN neutralizing antibodies.
Time frame: Baseline, 12 weeks, 24 weeks
Population: Due to small sample size, Pfizer did not perform statistical analysis.